Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
Part of paid clinical trials in Georgetown, Texas.
- Sponsor
- AbbVie
- Study ID
- NCT07227896
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Study Details
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across the world. Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 6 months. There are no additional examinations due to the study but the participants and caregivers will need to fill several questionnaires to generate data on their motor function and well-being
Key Dates
- First listed
- Nov 13, 2025
- Start date
- Aug 3, 2026
- Status verified
- Aug 2026
- Primary completion
- Oct 31, 2027
- Completion
- Oct 31, 2027
Study Design
- Enrollment
- 100 participants (estimated)
Arms
- Arm: Foslevodopa/FoscarbidopaParticipants will receive Foslevodopa/Foscarbidopa as prescribed by their physician according to local label.
Primary Outcome Measure
Change From Baseline in OFF Time (hours) as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV [ Time Frame: Up to approximately 6 months ]
Central Contacts
- Lars Bergmann+49(0)170 4538568
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Texas Movement Disorder Specialists /ID# 278565 | Georgetown | Texas | 78628 | - |
Find similar trials in Georgetown, TX
Related Studies
- Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS RegistryRecruiting · Boston Scientific Corporation · Los Angeles, California
- Parkinson's Foundation PD GENEration Genetic RegistryRecruiting · Parkinson's Foundation · Phoenix, Arizona
- A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's DiseasePHASE1 · Recruiting · Prevail Therapeutics · Englewood, Colorado
- A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseasePHASE3 · Recruiting · Hoffmann-La Roche · Birmingham, Alabama